Latigo Biotherapeutics Inc.
NASDAQ:LTGOMedical - Pharmaceuticals
+$0.76 today
- Market cap
- $800.64M
- Beta
- 0.00
Volume 0.21M
Average 0.38M
LTGO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Revenue history
Currency unavailable · from the income statement
No Revenue data reported for this period type.
Revenue vs competitors
How LTGO compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $796.33M USD | +19.9% | +18.9% | |
| LTM Mar 2026 | $734.86M USD | +4.6% | +2.9% | |
| LTM Mar 2026 | $33.86M USD | -33.2% | -7.3% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — |
| Peer median (excluding LTGO) | — | +4.6% | +2.9% | |
Competitors are the stored peer set for LTGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Latigo Biotherapeutics Inc.
NASDAQ:LTGO
Intrinsic Alpha fair value
Locked
Current Price
$13.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.